IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by J. Safra Sarasin Holding AG

Key Points

• J. Safra Sarasin Holding AG reduced its stake in IQVIA Holdings Inc. by 36.5% in the first quarter, now holding shares worth $2.25 million after selling 7,344 shares.
• Various institutional investors have increased their positions in IQVIA, with Pacer Advisors Inc. raising its stake by 5,036.1% and Invesco Ltd. increasing its holdings by 53.4%.
• IQVIA's recent earnings report showed an earnings per share of $2.81, exceeding analysts' expectations, with a revenue of $4.02 billion for the quarter.

J. Safra Sarasin Holding AG lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 36.5% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 12,766 shares of the medical research company's stock after selling 7,344 shares during the period. J. Safra Sarasin Holding AG's holdings in IQVIA were worth $2,251,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. American National Bank & Trust acquired a new stake in shares of IQVIA in the 1st quarter valued at $26,000. Golden State Wealth Management LLC grew its position in IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after purchasing an additional 130 shares during the last quarter. AllSquare Wealth Management LLC purchased a new stake in shares of IQVIA in the first quarter valued at about $33,000. ST Germain D J Co. Inc. boosted its holdings in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares in the last quarter. Finally, GKV Capital Management Co. Inc. purchased a new stake in shares of IQVIA in the fourth quarter valued at about $39,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research analyst reports. Redburn Partners set a $188.00 price objective on shares of IQVIA in a report on Friday, May 23rd. Mizuho lifted their target price on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. William Blair restated an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and cut their price objective for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Finally, Truist Financial boosted their price objective on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Seven analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $228.62.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

IQVIA Stock Down 0.6%

Shares of IQV stock traded down $1.10 on Tuesday, hitting $181.65. The stock had a trading volume of 194,473 shares, compared to its average volume of 2,015,448. The firm has a market capitalization of $30.88 billion, a price-to-earnings ratio of 26.27, a P/E/G ratio of 2.00 and a beta of 1.30. The stock's 50 day moving average is $163.03 and its 200-day moving average is $169.60. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm's quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.64 earnings per share. As a group, research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.